Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer: A Meta-Analysis

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.4, 2010-04, pp. : 229-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Response to Comments on “No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data”

By Hawkins Neil Scott David A. Thatcher Nicholas

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 683-683

Blackwell Publishing

Access to resources Recommend Favorite

Bevacizumab in Non-Small Cell Lung Cancer

By Francesco Di Costanzo

Drugs, Vol. 68, Iss. 6, 2008-01 ,pp. : 737-746

Adis International

Access to resources Recommend Favorite

Induction paclitaxel/carboplatin followed by radiotherapy and paclitaxel shows promising efficacy in unresectable non-small-cell lung cancer

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3689-3700

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab: a potential new option in the treatment of advanced breast or non-small-cell lung cancer

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 22, Iss. 9, 2006-09 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite